Many FH patients will require combination drug therapy. Only about 20% of patients with FH will reach the recommended LDL cholesterol target of <100 mg/dL, and therefore combination drug therapy will need to be utilized. A statin in combination with either ezetimibe, niacin, or again, colesevelam is to be preferred; the decision to use additional drug therapy in these patients should be guided by additional common risk factors for myopathies; other medications the patient may be taking; the presence of other disease conditions; and of course the patient’s lipid abnormalities.
J Clin Lipidol. 2011; 5(6).